Skip to main content
Fig. 1 | Cell Communication and Signaling

Fig. 1

From: ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production

Fig. 1

ARID1A deficiency changes the immune phenotype and enhances immune cell infiltration in lung adenocarcinoma patients with or without EGFR mutations. A ARID1A mutations were associated with longer overall survival in pancancer patients who received immunotherapy. B ARID1A mutations were associated with higher TMB values in pancancer patients. C ARID1A mutations were associated with higher TMB values in lung adenocarcinoma patients; D1, D2 Low ARID1A expression was associated with higher ESTIMATE scores, immune scores and IPS scores in lung adenocarcinoma patients. E Low ARID1A expression was associated with higher ESTIMATE scores, immune scores and IPS scores (anti-PD1/PD-L1) in lung adenocarcinoma patients harboring EGFR mutation. F Enrichment analysis for lung adenocarcinoma patients with low ARID1A expression. G Lung adenocarcinoma patients with low ARID1A expression had a higher infiltrating immune cell abundance

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X